IL-18 binding protein reverses the life-threatening hyperinflammation of a baby with the NLRC4 mutation

Journal of Allergy and Clinical Immunology

Volumn 140, Issue 1, 2017, Pages 316-

  Novick, Daniela ^a   Dinarello, Charles A ^b  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR; INTERLEUKIN 18; INTERLEUKIN 18 BINDING PROTEIN; REAGENT; CARRIER PROTEIN; INFLAMMASOME; INTERLEUKIN-18 BINDING PROTEIN; SIGNAL PEPTIDE;

ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; GENE MUTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LETTER; MACROPHAGE ACTIVATION SYNDROME; NLRC4 GENE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; GENETICS; MUTATION;

CARRIER PROTEINS; INFLAMMASOMES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-18; MUTATION;

EID: 85018248495     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2017.02.037     Document Type: Letter

References (9)

1. Canna, S.W., Girard, C., Malle, L., de Jesus, A., Romberg, N., Kelsen, J., et al. Life-threatening NLRC4-associated hyperinflammation successfully treated with interleukin-18 inhibition. J Allergy Clin Immunol, November 19, 2016, 10.1016/j.jaci.2016.10.022.
2. Novick, D., Kim, S.H., Fantuzzi, G., Reznikov, L.L., Dinarello, C.A., Rubinstein, M., Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 10 (1999), 127–136.
3. Kim, S.H., Eisenstein, M., Reznikov, L., Fantuzzi, G., Novick, D., Rubinstein, M., et al. Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc Natl Acad Sci U S A 97 (2000), 1190–1195.
4. Novick, D., Rubinstein, M., The tale of soluble receptors and binding proteins: from bench to bedside. Cytokine Growth Factor Rev 18 (2007), 525–533.
5. Novick, D., Schwartsburd, B., Pinkus, R., Suissa, D., Belzer, I., Sthoeger, Z., et al. A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine 14 (2001), 334–342.
6. Mazodier, K., Marin, V., Novick, D., Farnarier, C., Robitail, S., Schleinitz, N., et al. Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood 106 (2005), 3483–3489.
7. Put, K., Avau, A., Brisse, E., Mitera, T., Put, S., Proost, P., et al. Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ. Rheumatology 54 (2015), 1507–1517.
8. Shimizu, M., Yokoyama, T., Yamada, K., Kaneda, H., Wada, H., Wada, T., et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology (Oxford) 49 (2010), 1645–1653.
9. Shimizu, M., Nakagishi, Y., Inoue, N., Mizuta, M., Ko, G., Saikawa, Y., et al. Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Clin Immunol 160 (2015), 277–281.